Roche’s CT-388 shows promising results in Phase I trial for obesity and Type 2 diabetes treatment
Roche has announced positive outcomes from the Phase I clinical trial of CT-388, a novel dual GLP-1/GIP receptor agonist, which is being developed as a once-weekly subcutaneous injection for the treatment of obesity and type 2 diabetes. The trial results revealed significant weight loss and improved glycemic control in participants, positioning CT-388 as a potentially […]